Tresiba® now available in Scotland

By Editor
9th August 2016
Latest news

An alternative treatment to help improve glycaemic control for adults living with diabetes is now available in Scotland.

NHS Scotland can now prescribe Novo Nordisk’s Tresiba® (insulin degludec), to people with either type 1 or type 2 to help manage their blood sugar levels.

The Scottish Medicines Consortium approved the once-daily, long-acting basal insulin yesterday.

It comes after a recent report published by Diabetes UK found the country to have the worst record of HbA1c control in the western world.

More than 276,000 people live with either form of the condition in Scotland, a 25 per cent increase since 2008.

Nearly £1bn is spent annually on managing diabetes in the country, equating to nearly £100,000 every hour.

‘Larger portfolio of treatment’

Dr Russell Drummond, an expert in medicine from Glasgow Royal Infirmary, welcomed the news.

He said: “People living with diabetes face various challenges on a daily basis, particularly when they are taking insulin.

“Balancing activity, diet, work, children and driving, all whilst having to consistently measure and manage blood sugars can be difficult.

“Hypoglycaemia, low blood sugar, is a common and major concern for my patients, especially at night when it is harder to detect and manage.”

“A larger portfolio of treatment is beneficial to our practice and insulin degludec, in particular, has a place in treatment for adults with diabetes, particularly those with type 1 diabetes who face challenges with hypoglycaemia on insulin therapy.”

Insulin degludec received its first regulatory approval in September 2012 and has since been approved in more than 60 countries across the world.

Rahul Kapur, head of medical affairs at Novo Nordisk UK said: “We are delighted to be able to offer people with type 1 and type 2 diabetes in Scotland access to a treatment that can help to manage blood glucose levels and also help with some of the challenges associated with insulin, like hypoglycaemia.”

Comments (0)

Register an account or login to comment